Physician profile
James D Dillon
NPI 1285736702
$3,372.30
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $410 · 2020: $245 · 2021: $960 · 2022: $1,009 · 2023: $708 · 2024: $39.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $748.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $747.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $333.39 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $269.46 | 2021-2023 | Ingrezza, Ongentys |
| Amgen INC. | $246.65 | 2020-2023 | Aimovig |
| Abbvie INC. | $238.47 | 2022-2024 | Botox, Ubrelvy |
| Teva Pharmaceuticals USA, INC. | $208.36 | 2021-2023 | Austedo |
| Eisai INC. | $184.44 | 2021-2023 | |
| Sk Life Science, INC. | $171.12 | 2022-2023 | |
| Medtronic USA, INC. | $167.72 | 2019 | |
| Arbor Pharmaceuticals, INC. | $117.86 | 2021 | |
| Argenx US, INC. | $112.41 | 2022-2023 | Vyvgart |
| Upsher-Smith Laboratories LLC | $80.93 | 2020-2021 | |
| Alexion Pharmaceuticals, INC. | $79.29 | 2020-2023 | Ultomiris |
| Emd Serono, INC. | $78.77 | 2021-2022 | |
| Lundbeck LLC | $73.76 | 2022-2023 | Vyepti |
| Depuy Synthes Sales INC. | $71.35 | 2019 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Dillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.